Flt Signaling Can be brought within 30 days

That it preceded a benefit of cabazitaxel over mitoxantrone in patients w During docetaxel therapy and in which L Ngerfristige dosage of docetaxel shown. In the TROPIC study, the median Flt Signaling time between the last dose of docetaxel was progression less than a month, since these patients were heavily pretreated with a median of 7 cycles of docetaxel TROPIC before registration. However, it should be noted that with cabazitaxel significant toxicity t K and death Can be brought within 30 days in connection after the last dose were reported in 4.9% of patients. This toxicity t was Haupt Chlich k for myelosuppression, but diarrhea Can be severe. First monitoring cycle blood counts is recommended and prim Re prophylaxis with G-CSF for M men’s over 65 and for those with a poor performance status, previous episodes of febrile neutropenia, extensive connections recommended radiation earlier bad Ern Channel condition or other serious comorbidities .
Abiraterone acetate CO AA 301 antiandrogen therapy is con Ue more androgen mediated signaling, which can be inhibited by the adrenal androgen mediated residual in prostate tissue. The vorl INDICATIVE analysis of the study NECK AA 301 was recently reported at the European Society Dehydrogenase of Medical Oncology 2010 Congress. This study evaluated the safety and efficacy of abiraterone acetate plus prednisone was treated with a placebo and prednisone in nnern M With mCRPC previously with docetaxel, compared with the primary Ren endpoint’s operating system. AA is an analogue of pregnenolone orally, still significantly reduced in CRPC androgen by inhibition of CYP17, a rate-limiting enzyme in the biosynthesis of androgens.
This drug has shown activity t In mCRPC with acceptable toxicity T have in Phase 1 trials. Side effects associated with this agent principle Z Select hypertension, Hypokali mie Deme, min??ralocortico manageable with the antagonists Corticosteroids or Low dose appears. In NECK AA 301, the water retention time and were Hypokali Mie h With AA more frequently compared to placebo, w During Hypokali Mie Grade 3 or 4 hypertension were rarely observed. The efficacy results of the tests prompted the Independent Data Monitoring recommended unblinding of the study at the time of the interim analysis and the intersection of the patients in the placebo group to AA.
These results showed a significant improvement in overall survival, time to PSA progression, radiographic PFS and PSA response rates in patients with AA compared with placebo. The results best term That CO 301 AA targeting persistent androgen biosynthesis a viable treatment option for M Men with progressive disease despite medical or surgical castration. A new drug application with U.S. regulators filed in December 2010, has abiraterone / prednisone currently being evaluated in a Phase 3 trial in metastatic CRPC patients receiving chemotherapy have ?. As previously indicated MDV3100, k Can treatments that effectively block AR activity t Directly opposite as to remove residual androgen have therapeutic value in CRPC. MDV3100 is an AR antagonist.